<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949754</url>
  </required_header>
  <id_info>
    <org_study_id>API092</org_study_id>
    <nct_id>NCT00949754</nct_id>
  </id_info>
  <brief_title>Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation</brief_title>
  <acronym>HBV</acronym>
  <official_title>A Multi-Center, Randomized, Double Blind, Active-Controlled, Parallel Group Clinical Study to Evaluate the Dose Effect of Intradermal Injections of Apitox vs. Histamine in Subjects With Osteoarthritis Symptoms of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apimeds, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apimeds, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate Apitox, pure honeybee venom as a treatment for pain and inflammation
      of osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>histamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>histamine in saline administered ID as active control for Apitox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apitox pure honeybee venom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ID study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>honeybee venom (Apitoxin (Korea) Apitox (USA))</intervention_name>
    <description>multiple intradermal injections of 100 ug pure honeybee venom</description>
    <arm_group_label>histamine</arm_group_label>
    <arm_group_label>Apitox pure honeybee venom</arm_group_label>
    <other_name>Apitoxin (Korea) Apitox (USA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  osteoarthritis of one or both knees

          -  on stable NSAID or none due to intolerance

          -  women either post menopausal or on stable birth control

          -  no clinically significant disease or or abnormal laboratory values

          -  signed informed consent, communicate effectively, understand and comply with all study
             requirements

        Exclusion Criteria:

          -  serious or unstable medical or psychological condition

          -  known sensitivity to honeybee venom, histamine or lidocaine

          -  history of asthma

          -  any clinically significant ECG abnormalities

          -  any clinically significant laboratory values OOR

          -  history of drug or alcohol abuse

          -  history of joint injury and forms of inflammatory arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher MH Kim, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Apimeds, CEO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Brooks, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Apimeds, Inc, US Chief Operating Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>May 4, 2010</last_update_submitted>
  <last_update_submitted_qc>May 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Brooks PhD, Chief Operating Officer US</name_title>
    <organization>Apimeds, Inc.</organization>
  </responsible_party>
  <keyword>honeybee venom</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <keyword>knees</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

